Cortex Pharmaceuticals Inc. (CORX) to Buy Back AMPAKINE Assets and Intellectual Property

QualityStocks would like to highlight Cortex (OTCBB: CORX). Located in Irvine, California, Cortex is a neuroscience company focused on novel drug therapies for treating psychiatric disorders, neurological diseases and sleep apnea. Cortex is pioneering a class of proprietary pharmaceuticals called AMPAKINE® compounds, which act to increase the strength of signals at connections between brain cells. The loss of these connections is thought to be responsible for memory and behavior problems in Alzheimer’s disease.

In the company’s news yesterday,

Cortex Pharmaceuticals has entered into an agreement with Biovail Laboratories International SLR, a wholly owned subsidiary of Valeant Pharmaceuticals International Inc., to regain the AMPAKINE® assets and rights related to respiratory depression.

The new agreement follows Biovail’s purchase of the rights and compounds from Cortex in March 2010. Following the September 2010 merger of Biovail and Valeant, a financial review of the product development pipeline led the combined company to make the decision that Biovail would exit the program, allowing for discussions between Biovail and Cortex.

Per the new agreement, Cortex will make a $200,000 upfront payment to Biovail in addition to potential future payments of up to $15.15 million based on the achievement of certain development and NDA submission and approval milestones. Biovail is also eligible to receive additional payments based on Cortex’s net sales of an intravenous dosage form of the compounds for respiratory depression up to a maximum of $15 million. Biovail also retains an option to co-develop and co-market intravenous dosage forms of AMPAKINE following completion of phase I clinical studies and prior to the end of phase IIa clinical studies.

“We are pleased that both companies were able to reach an agreement for the return of all AMPAKINE assets and intellectual property sold early last year to Biovail,” Mark A. Varney, Ph.D., president and CEO of Cortex stated in the press release.

According to the press release, the assets repurchased by Cortex include the phase II AMPAKINE, CX717; the rights to an injectable form of CX1739 and all dosage forms of CX1942, the first water soluble intravenous pro-drug for an AMPAKINE compound; and the exclusive global patent rights for the use of AMPAKINE compounds for the treatment of respiratory depression. In accordance with the original agreement with Biovail, Cortex had retained rights to all non-intravenous dosage forms of CX1739 and to the use of AMPAKINE compounds as a treatment for sleep apnea.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.